在三阴性乳腺癌中MAGE-A:分子生物学,表观遗传向和免疫治疗
Nik Mohd Asri Nik Amirah Auni1, Norhanani Mohd Redzwan1, Faezahtul Arbaeyah Hussain2
1Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
Epigenomics
|December 10, 2025
概括
MAGE-A 蛋白质是三阴性乳腺癌 (TNBC) 的有希望的治疗点. 针对MAGE-A的免疫疗法,就像类疫苗一样,在临床前研究中显示出有效性,并正在推进对TNBC治疗的临床试验.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- MAGE-A蛋白在各种固体瘤中表达,特别是三阴性乳腺癌 (TNBC).
- 在TNBC中MAGE-A表达与通过AMPK降解和p53下调等途径增加的侵入性和转移相关.
- 表观遗传机制,包括DNA甲基化和非编码RNA,调节MAGE-A的表达.
研究的目的:
- 审查MAGE-A家族成员作为TNBC中的目标的治疗潜力.
- 讨论针对TNBC中MAGE-A的新型免疫治疗策略.
主要方法:
- 对TNBC中MAGE-A表达和功能的临床前研究的审查.
- 对MAGE-A向免疫疗法的分析,包括基于的疫苗.
- 检查正在进行的TNBC中MAGE-A免疫疗法的早期临床试验.
主要成果:
- MAGE-A在TNBC中比其他乳腺癌亚型更为普遍.
- MAGE-A促进了TNBC细胞上皮层-介质细胞过渡和转移.
- 临床前的MAGE-A疫苗诱导T细胞对TNBC细胞的反应.
结论:
- MAGE-A代表了TNBC的一个可行的治疗点.
- 多表位MAGE-A疫苗提供了一种克服MAGE-A异质性和MHC限制的策略.
- 涉及MAGE-A疫苗和表观遗传药物的组合疗法可能会改善TNBC患者的临床结果.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


